A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) (NCT06163534)
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
🩺 Plain-English Summary (8th-Grade Level)
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (30 Sites)
Showing the first 25 of 30 sites.
- City of Hope — Duarte, California
- USC/Norris Comprehensive Cancer Center — Los Angeles, California
- University of California, Los Angeles — Los Angeles, California
- Stanford — Palo Alto, California
- Providence Medical Foundation — Santa Rosa, California
- Morehouse — Atlanta, Georgia
- Piedmont Healthcare — Atlanta, Georgia
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Northwestern University Feinberg School of Medicine — Chicago, Illinois
- Cancer Care Specialists of Illinois — Decatur, Illinois
- Illinois Cancer Care — Peoria, Illinois
- University of Kansas — Westwood, Kansas
- University of Maryland — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Henry Ford — Detriot, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Oncology Hematology Associates — Springfield, Missouri
- Washington University in St. Louis — St Louis, Missouri
- Mount Sinai Hospital — New York, New York
- Sanford Fargo — Fargo, North Dakota
- University of Cincinnati — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Ohio State University — Columbus, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- Cancer Care Associates of York — York, Pennsylvania
📞 Contact the Study Coordinator
Phone: (833) 514-4187
Email: phoenix@tempus.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Head and Neck Squamous Cell Carcinoma
- Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Fullerton, California
- Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck — Duarte, California
- MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients — Gilbert, Arizona
- Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 — St Louis, Missouri
- Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial — Buffalo, New York
- Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca — Baltimore, Maryland
Explore by condition: All Head and Neck Squamous Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.